Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Nephropathy
Interventions: placebo, atorvastatin; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Nasal Polyps
Interventions: Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more

Conditions: Degenerative Disc Disease
Interventions: Intradiscal rhGDF-5, Water for injection; Drug · Other
Lead sponsor: DePuy Spine; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more

Conditions: Cerebral Edema, Saline Solution, Hypertonic
Interventions: 3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stereotypical Prolonged Seizures
Interventions: Staccato alprazolam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 12 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 66
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more

Conditions: Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Zimmer Biomet; Industry
Eligibility: Not listed
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 5
States / cities: Rockville, Maryland • Lima, Ohio • West Chester, Ohio + 2 more

Conditions: Prevention, Control
Interventions: Mindfulness Program, Active Comparator; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Evanston, Illinois • Nashville, Tennessee

Conditions: Postherpetic Neuralgia, Pain
Interventions: V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 28
States / cities: Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more

Conditions: Phantom Limb Pain
Interventions: Farabloc Limb Cover, Sham Limb Cover; Device
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Vatelizumab, Placebo (for Vatelizumab); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Active Provant Therapy System, Inactive (sham) Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Interstitial Cystitis
Interventions: Pentosan polysulfate sodium 100 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 52
States / cities: Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 49 more

Conditions: Depression, Depression, Anxiety, Inflammation
Interventions: Freeze Dried Blueberry Powder - 71717, USHBC Blueberry Placebo Formula #114; Dietary Supplement
Lead sponsor: Louisiana State University, Baton Rouge; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Cottonport, Louisiana • Marksville, Louisiana

Conditions: Complicated Intra-abdominal Infections
Interventions: Ceftazidime -avibactam, Meropenem, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Toledo, Ohio + 1 more

Conditions: Pain, Ankle Injuries
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Traumatic Brain Injury
Interventions: BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery), Usual Care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Crohn Disease
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 77
States / cities: Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more

Conditions: Autism, Severe Behavior Disorder
Interventions: placebo, glutathione, glutathione, vit C and NAC; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 5 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Necrotizing Enterocolitis
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 2 Weeks to 8 Weeks
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more

Conditions: Attention Deficit Hyperactivity Disorder Combined
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Donald Gilbert, MD, MS, FAAN, FAAP; Other
Eligibility: 8 Years to 12 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Crohn Disease
Interventions: JNJ-78934804, Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 29
States / cities: Scottsdale, Arizona • Sun City, Arizona • Anaheim, California + 26 more

Conditions: Burnout Among First Year Residents
Interventions: Online MedEd Intern Bootcamp; Behavioral
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Manhattan, New York

Search by objective public record fields.

Efficacy of Statins In Prevention of CIN

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement

A Randomized Controlled Trial Testing the Effect of the Youth Mindful Awareness Program on Negative Affect (YMAP2).

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Controlled Study of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

Effect of Whole Blueberry Powder Consumption on Depression in a Central Louisiana Population

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

Associated Joint Pain With Controlled Ankle Movement (CAM) Walker Boot Wear

BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery)

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Online MedEd Intern Bootcamp: Online Training for First Year Residents